Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans.

18 Nov 2010

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Exelixis, Inc. today reported interim data from the cohort of patients with advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Merck announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee has advised that the data presented support an indication for GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer and anal intraepithelial neoplasia (AIN) in both males and females 9 through 26 years of age.

18 Nov 2010

A.P. Pharma third quarter net loss increases to $1.7 million

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2010.

15 Nov 2010

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Santarus, Inc., a specialty biopharmaceutical company, today announced the commercial U.S. launch of CYCLOSET (bromocriptine mesylate) tablets. CYCLOSET is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus both as monotherapy and in combination with other oral antidiabetic agents.

15 Nov 2010

New 'magic bullet' can eradicate side effects of drug used to treat cystinosis

A 'magic bullet' designed by pharmaceutical scientists at an English university could eradicate the side effects of a drug used to treat a rare genetic disease. Researchers at the University of Sunderland have chemically modified a drug used to treat cystinosis a disease which occurs when the body's mechanism to remove excess cystine (an amino acid) breaks down, leading to kidney problems and eventually affecting other organs to remove unpleasant side effects such as nausea, vomiting, severe halitosis, body odour and a noxious taste.

11 Nov 2010

MonoSol Rx granted U.S. patent for PharmFilm and production technologies

MonoSol Rx, the developers of PharmFilm® technology and a drug delivery company specializing in proprietary pharmaceutical film products, today announced that it has been granted U.S. patent No. 7,824,588 from the United States Patent and Trademark Office (USPTO). The patent, issued on November 2, 2010, provides intellectual property protection for the Company's film products and methods of their preparation.

10 Nov 2010

Cholera confirmed in Haiti's capital as health ministry says outbreak has killed 544 so far

Haiti's cholera outbreak appears to have spread to its capital, "imperiling nearly 3 million people living in Port-au-Prince, nearly half of them in unsanitary tent camps for the homeless from the Jan. 12 earthquake," the Associated Press/KIRO reports.

10 Nov 2010

NeoPharm, Insys complete merger

NeoPharm, Inc., a biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced it has completed its merger with Insys Therapeutics, Inc., a Phoenix, AZ based pharmaceutical company.

10 Nov 2010

Semafore's SF1126 for B-cell chronic lymphocytic leukemia granted FDA orphan drug designation

Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).

9 Nov 2010

Chemotherapy for breast cancer does more harm than good

A fundamental principle of medicine is: "first, do no harm." However, for doctors who treat breast cancer, this is easier said than done. Every year, almost 22,000 Canadian women are diagnosed with breast cancer - their treatment usually involves surgery to remove a tumour and then chemotherapy to reduce the risk of cancer returning.

9 Nov 2010

SIMPONI injection improves inflammation, structural damage in RA patients

Magnetic resonance imaging (MRI) analyses from two Phase 3 clinical trials showed that once every four week subcutaneous injections of SIMPONI (golimumab) 50 mg plus methotrexate resulted in statistically significant improvements in markers of inflammation and structural damage in patients with active rheumatoid arthritis (RA) compared with placebo plus methotrexate.

9 Nov 2010

Family history of HG increases risk of extreme morning sickness during pregnancy

Approximately 60,000 pregnant women are hospitalized each year due to hyperemesis gravidarum (HG), an extreme form of nausea and vomiting that endangers their lives and often forces them to reluctantly terminate their pregnancies.

9 Nov 2010

MAP Pharmaceuticals reports positive results from LEVADEX QT trial for migraine

MAP Pharmaceuticals, Inc. today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals. LEVADEX is a novel orally inhaled migraine therapy that has completed Phase 3 efficacy development for the acute treatment of migraine.

8 Nov 2010

Prophylaxis can prevent postoperative nausea and vomiting

Vomiting is unpleasant. Nearly 30% of all patients suffer from nausea and vomiting after surgery. The financial repercussions of this are longer patient stays in the recovery room, with increased need for personnel. Appropriate prophylaxis and treatment can prevent postoperative nausea and vomiting. In a systematic review of the literature, Dirk Rüsch and co-authors investigate how treatment recommendations for nausea after general anesthesia can be improved.

8 Nov 2010

Inviragen to present data on CHIKV vaccine at ASTMH meeting

Inviragen, a biotechnology company developing vaccines to protect against infectious diseases worldwide, together with investigators at the University of Texas Medical Branch (UTMB) and the Division of Vector Borne Diseases (DVBD) of the Centers for Disease Control and Prevention, will make an oral presentation today at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting on preclinical results of the Company's experimental chikungunya virus (CHIKV) vaccine.

8 Nov 2010

Phase III study suggests CYCLOSET tablets improve glycemic control

Santarus, Inc. and VeroScience LLC today announced that analyses of 379-patient subset data from a 3,070-patient Phase III safety study conducted with CYCLOSET (bromocriptine mesylate) tablets suggested that CYCLOSET as an add-on to oral antidiabetes drugs produced improvements in glycemic control irrespective of baseline duration of disease.

4 Nov 2010

Acton submits Manufacturing Supplement to FDA for AEROSPAN Inhalation Aerosol

Acton Pharmaceuticals, Inc. today announced that it has submitted to the U.S. Food and Drug Administration (FDA), a Manufacturing Supplement to the previously approved AEROSPAN Inhalation Aerosol NDA.

4 Nov 2010

SYMBICORT improves lung function in African American asthma patients compared to budesonide alone

AstraZeneca announced today that results from TITAN, a 12-week study of SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol in African American patients with moderate to severe persistent asthma, showed significant improvement in lung function for patients taking SYMBICORT compared with those using budesonide alone.

3 Nov 2010

Hyperion HPN-100 phase III pivotal study for urea cycle disorders meets primary endpoint

Hyperion Therapeutics, Inc. today announced that the Company's phase III pivotal study of glycerol phenylbutyrate (HPN-100), an investigational drug for the treatment of urea cycle disorders (UCDs), met its primary endpoint. The non-inferiority study, conducted under a Special Protocol Assessment (SPA) granted by the U.S. Food and Drug Administration (FDA) in June 2009, evaluated the ammonia control of glycerol phenylbutyrate as compared to sodium phenylbutyrate (BUPHENYL®).

3 Nov 2010

Vomiting News and Research

Further Reading

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

A.P. Pharma third quarter net loss increases to $1.7 million

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

New 'magic bullet' can eradicate side effects of drug used to treat cystinosis

MonoSol Rx granted U.S. patent for PharmFilm and production technologies

Cholera confirmed in Haiti's capital as health ministry says outbreak has killed 544 so far

NeoPharm, Insys complete merger

Semafore's SF1126 for B-cell chronic lymphocytic leukemia granted FDA orphan drug designation

Chemotherapy for breast cancer does more harm than good

SIMPONI injection improves inflammation, structural damage in RA patients

Family history of HG increases risk of extreme morning sickness during pregnancy

MAP Pharmaceuticals reports positive results from LEVADEX QT trial for migraine

Prophylaxis can prevent postoperative nausea and vomiting

Inviragen to present data on CHIKV vaccine at ASTMH meeting

Phase III study suggests CYCLOSET tablets improve glycemic control

Acton submits Manufacturing Supplement to FDA for AEROSPAN Inhalation Aerosol

SYMBICORT improves lung function in African American asthma patients compared to budesonide alone

Hyperion HPN-100 phase III pivotal study for urea cycle disorders meets primary endpoint

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News